A dual-targeted lentiviral vector homing in on prostate bone metastases

Molecular Therapy

Volumn 15, Issue 11, 2007, Pages 1906-1908

  Hu, Yufang ^a   Stout, David ^b   Wu, Lily ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; GLYCOPROTEIN E1; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN G; LENTIVIRUS VECTOR; LUCIFERASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1G8; PROSTATE STEM CELL ANTIGEN; PROTEIN A; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

BONE METASTASIS; CANCER GENE THERAPY; CELL HOMING; DNA MODIFICATION; DRUG TARGETING; GENE TECHNOLOGY; GENETIC TRANSDUCTION; HUMAN; NOTE; PROMOTER REGION; PROSTATE CANCER; SINDBIS VIRUS; TUMOR CELL; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 35548982600     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300317     Document Type: Note

References (17)

1. Thomas, CE, Ehrhardt A and Kay, MA (2003). Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4: 346-358.
2. Lavillette, D, Russell, SJ and Cosset, FL (2001). Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotecthnol 12: 461-466.
3. Sanders, DA (2002). No false start for novel pseudo-typed vectors. Curr Opin Biotechnol 13: 437-442.
4. Breckpot, K, Aerts, JL and Thielemans, K (2007). Lentiviral vectors for cancer immunotherapy: Transforming infectious particles into therapeutics. Gene Ther 14: 847-862.
5. Pariente, N, Morizono, K, Virk, MS, Petrigliano, FA, Reiter, RE, Lieberman, JR et al. (2007). A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther. 15: 1973-1981.
6. Follenzi, A, Sabatino, G, Lombardo, A, Boccaccio, C and Naldini, L (2002). Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 13 243-260.
7. Yu, D, Chen, D, Chiu, C, Razmazma, B, Chow YH and Pang, S (2001). Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 8: 628-635.
8. Naldini, L, Blomer, U, Gallay, P, Ory, D, Mulligan, R, Gage, FH et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
9. Reynolds, PN, Nicklin, SA, Kaliberova, L, Boatman, BG, Grizzle, WE, Balyasnikova, IV et al. (2001). Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 19: 838-842.
10. Muller, OJ, Leuchs, B, Pleger, ST, Grimm, D, Franz, WM, Katus, HA et al. (2006). Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 70: 70-78.
11. Wu, L, Matherly, J, Smallwood, A, Adams, JY, Billick, E, Belldegrun, A et al. (2001). Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther 8: 1416-1426.
12. Morizono, K, Bristol, G, Xie, YM, Kung, SK and Chen, IS (2001). Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 75: 8016-8020.
13. Morizono, K, Xie, Y, Ringpis, GE, Johnson, M, Nassanian, H, Lee, B et al. (2005). Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 11 346-352.
14. Lam, JS, Yamashiro, J, Shintaku, IP, Vessella, RL, Jenkins, RB, Horvath, S et al. (2005). Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 11: 2591-2596.
15. Logothetis, CJ and Lin, SH (2005). Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5: 21-28.
16. Bagi, CM (2005). Targeting of therapeutic agents to bone to treat metastatic cancer. Adv Drug Deliv Rev 57: 995-1010.
17. Weinberg, RA (2007). The Biology of Cancer. Garland Science: New York.